Skip to main content
SpringerLink
Log in

Medikamentöse Therapie

  • Chapter
Qualitätssicherung in der Rheumatologie

Part of the book series: Qualitätssicherung in der Rheumatologie ((QUALRHEUM,volume 1))

  • 1169 Accesses

Auszug

Nichtsteroidale Antirheumatika (NSAR) haben entzündungshemmende, schmerz stillende und fiebersenkende Eigenschaften. Sie sind mit Ausnahme der meisten zugelassenen COX-2-selektiven Inhibitoren (s. Kap. 5.1.2) saure Verbindungen, die im Plasma zu über 99% an Proteine gebunden sind. Chemisch weisen NSAR heterogene Strukturen auf (s. u.). Ihr Wirkungsmechanismus ist komplex. Die Hemmung der Prostaglandinsynthese via Cyclooxygenase-(COX-)Inhibition gilt als ihr wichtigster und bestuntersuchter Wirkmechanismus. Einige NSAR sollen ihre Wirkung zusätzlich durch Inhibition von Lipoxygenasen (LOX) entfalten. Andere sollen Einfluss auf die Zytokinsynthese nehmen. NSAR sind bei den meisten schmerzhaften rheumatischen Erkrankungen Mittel der Wahl, wenn saure Analgetika wie Parazetamol nicht ausreichend wirksam sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Mutschler Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie, 8. Aufl. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  2. Schmidt KL (1991) Checkliste Rheumatologie. Thieme, Stuttgart New York

    Google Scholar 

  3. Tannenbaum H, Bombardier C, Davis P, Russell AS (2006) An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 33:140–157

    PubMed  Google Scholar 

  4. Bolten WW (2005) Recommendations for treatment with nonsteroidal antiinflammatory drugs. MMW Fortschr Med 147:24–27

    PubMed  CAS  Google Scholar 

Literatur

  1. Hawkey CJ (1999) COX-2-Inhibitors. Lancet 353:307–314

    Article  PubMed  CAS  Google Scholar 

  2. Hinz B, Brune K (1999) Spezifische COX-2-Inhibitoren: Perspektiven einer Therapie mit neuen analgetischen und antiinflammatorischen Wirkstoffen. Wien Klin Wochenschr 111:103–112

    PubMed  CAS  Google Scholar 

  3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study [see comments]. JAMA 284[10]:1247–1255

    Article  PubMed  CAS  Google Scholar 

  4. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G (2006) Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119:255–266

    Article  PubMed  CAS  Google Scholar 

  5. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351: 1709–1711

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A metaanalysis. Arm Int Med 115:787–796

    CAS  Google Scholar 

  2. Graham DY, Agrawl NM, Roth SH (1988) Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre double blind, placebo-controlled trial. Lancet 11: 1277–1280

    Article  Google Scholar 

  3. Bolten W, Häntzschel H, Hengels KJ, Stockbrügger R (1991) Management der NSAR-assoziierten Gastropathie. Akt Rheumatol 16:171–174

    Google Scholar 

  4. Kneitz C, Tony HP, Kruger K (2006) NSAIDs and COX-2-inhibitors: current status. Internist (Berl) 47:533–540

    Article  CAS  Google Scholar 

  5. Bolten WW (2005) Recommendations for treatment with nonsteroidal antiinflammatory drugs. MMW Fortschr Med 147:24–27

    PubMed  CAS  Google Scholar 

  6. Spiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F (2006) Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 119:448–536

    Article  PubMed  CAS  Google Scholar 

  7. Laine L (2004) Proton pump inhibitor co-therapy with nonsteroidal antiinflammatory drugs-nice or necessary? Rev Gastroenterol Disord 4(suppl 4):S33–41

    Google Scholar 

Literatur

  • Buttgereit F, Da Silva JA, Boers M, Burmester GR, Cutolo M et al (2002) Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 61:718–722

    Article  PubMed  CAS  Google Scholar 

  • Kaiser H (2000) Corticoide in der Rheumatologie-gestern-heute-morgen. Z Rheumatol 59:75–85

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39:713–722

    Article  Google Scholar 

  2. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 39:723–731

    Article  Google Scholar 

  3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RI, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  4. Csuka ME, Carrera GF, McCarty DJ (1986) Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. J Am Med Assoc 255:2315–2319

    Article  CAS  Google Scholar 

  5. DGRh-Leitlinie: Management der frühen rheumatoiden Arthritis (2007) Schneider M, Lelgemann M, Abholz H, Caratte R, Flügge C, Jäniche H, Krüger K, Rehart S, Specker C. 2. überarbeitete Auflage, Steinkopff Verlag Darmstadt

    Google Scholar 

  6. Felson DT, Anderson JJ, Meenan RF (1994) The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 37:1487–1491

    Article  PubMed  CAS  Google Scholar 

  7. Hawley DJ, Wolfe F (1991) Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 18:1008–1014

    PubMed  CAS  Google Scholar 

  8. Heurkens AHM, Westedt ML, Breedfeld FC (1991) Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 151:224–254

    Article  Google Scholar 

  9. Iglehart IW, Sutton JD, Bender JC, Shaw RA, Ziminski CM, Holt PA, Hochberg MC, Zizic TM, Engle EW, Stevens MB (1990) Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study. J Rheumatol 17:159–162

    PubMed  Google Scholar 

  10. Ostensen M (1996) Medikation and Schwangerschaft. Rheumatol Europa 25:70–73

    Google Scholar 

  11. Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308–1315

    Article  PubMed  CAS  Google Scholar 

  12. Scott DGI, Bacon PA (1984) Intravenous cyclophosphamide plus methyl-prednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76:377–384

    Article  PubMed  CAS  Google Scholar 

  13. Shiroky JB, Neville C, Skelton JD (1992) High dose intravenous methotrexate for refractory rheumatoid arthritis. J Rheumatol 19:247–251

    PubMed  CAS  Google Scholar 

  14. Williams HJ, Reading JC, Ward JR, O’Brian WM (1980) Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 23:521–527

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Allen RC, Gross KR, Laxer RM, Malleson PN, Beauchamp RD, Petty RE (1986) Intraarticular triamcinolon hexacetonide in the management of chronic arthritis in children. Arthritis Rheum 29:997–1001

    Article  PubMed  CAS  Google Scholar 

  2. Ansell BM (1993) Cyclosporin A in paediatric rheumatology. Clin Exp Rheumatol 11:113–115

    PubMed  CAS  Google Scholar 

  3. Breit W, Frosch M, Meyer U, Heinecke A, Ganser G (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27:2696–2702

    PubMed  CAS  Google Scholar 

  4. Cassidy JT, Petty RE (2001) Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology. WB Saunders Company, Philadelphia, pp 218–321

    Google Scholar 

  5. Cron RQ, Sharma S, Sherry DD (1999) Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol 26:2036–2038

    PubMed  CAS  Google Scholar 

  6. David J, Vouyiouka O, Ansell BM, Hall A, Woo P (1993) Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 11:85–90

    PubMed  CAS  Google Scholar 

  7. Deutsche Rheumaliga, Elternkreise rheumakranker Kinder (1993) Mein Kind hat Rheuma-was kann ich tun? Druck Carl Weyler KG, Bonn

    Google Scholar 

  8. Foeldvari I, Thon A, Burgos-Vargas R (2000) 70% der Patienten mit juveniler rheumatoider Arthritis sprachen nach 12 Wochen auf eine Therapie mit Meloxicam-Suspension im Rahmen einer Phase I/II Studie an. Z Rheumatol 59(suppl 3):III/49

    Google Scholar 

  9. Gattinara M, Lomater C, Gerloni V, Fatini F (1994) Cyclosporin in pediatric rheumatology; a seven years experience. Acta Univ Carol 40:105–108

    CAS  Google Scholar 

  10. Gerloni V, Pontikaki I, Desiati F, Gattinara M, Fantini F (2000) Infliximab in the treatment of persistently active refractory juvenile idiopathic (chronic) arthritis: a short-term pilot study. Arthritis Rheum 43(suppl):S 256

    Google Scholar 

  11. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS, for the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children’s Study Group (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 326:1043–1049

    Article  PubMed  CAS  Google Scholar 

  12. Giannini EH, Cassidy JT (1993) Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks? Drug Saf 9:325–329

    PubMed  CAS  Google Scholar 

  13. Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N (1996) Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Collaborative Study Group. J Rheumatol 23:919–924

    PubMed  CAS  Google Scholar 

  14. Groothoff JW, van Leeuwen EF (1988) High dose intravenous gammaglobulin in chronic systemic juvenile arthritis. Br Med J 296:1362–1363

    CAS  Google Scholar 

  15. Halle F, Prieur AM (1991) Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 9:297–302

    PubMed  CAS  Google Scholar 

  16. Häfner R (2002) Juvenile idiopathische Arthritis. Die neue Nomenklatur und Klassifikation der chronischen Arthritis im Kindesalter. Akt Rheumatol 27:18–21

    Article  Google Scholar 

  17. Häfner R, Spamer M (1998) Rehabilitation of children. In: Maddison PJ, Isenberg Da, Woo P, Glass DN (eds) Oxford Textbook of Rheumatology. Oxford University Press, Oxford, pp 1737–1755

    Google Scholar 

  18. Häfner R, Truckenbrodt H, Michels H, von Altenbockum C (1991) Therapie der juvenilen chronischen Arthritis. Dt Ärzteblatt 88:2402–2407

    Google Scholar 

  19. Horneff G, Forster J, Seyberth HW, Michels H, für die Arbeitsgemeinschaft Kinderund Jugendrheumatologie (2000) Empfehlungen der Arbeitsgemeinschaft Kinderund Jugendrheumatologie zur Therapie mit Etanercept (P75 TNF-alpha-Rezeptor-Immunglobulinfusionsprotein). Kommission Pharmakotherapie. Z Rheumatol 59: 365–369

    Article  PubMed  CAS  Google Scholar 

  20. Huppertz HI, Tschammier A, Horwitz A, Schwab O (1995) Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr 127:317–321

    Article  PubMed  CAS  Google Scholar 

  21. Jung JH, Jun JB, Yoo DH, Kim TH, Jung SS, Lee IH, Bae SC, Kim SY (2000) High toxicity of sulfasalazine in adult-onset Still’s disease. Clin Exp Rheumatol 18: 245–248

    PubMed  CAS  Google Scholar 

  22. Kilmartin DJ, Forrester JV, Dick AD (1998) Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 82:737–742

    PubMed  CAS  Google Scholar 

  23. Krugmann J, Sailer-Hock M, Muller T, Gruber J, Allerberger F, Offner FA (2000) Epstein-Barr virus-associated Hodgkin’s lymphoma and legionella pneumophila infection complicating treatment of juvenile rheumatoid arthritis with methotrexate and cyclosporine A. Hum Pathol 31:253–255

    Article  PubMed  CAS  Google Scholar 

  24. Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13:118–123

    PubMed  CAS  Google Scholar 

  25. Lahdenne P, Honkanen V (2000) Infiximab vs. etanercept in the treatment of severe juvenile chronic arthritis (JCA). Arthritis Rheum 43(suppl):S 381

    Google Scholar 

  26. Lehmann TJA (1993) Aggressive therapy for childhood rheumatic diseases. When are immunosuppressives appropriate? Arthritis Rheum 36:71–74

    Article  Google Scholar 

  27. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342: 763–769

    Article  PubMed  CAS  Google Scholar 

  28. Michels H (1997) Is there a renaissance of corticosteroid therapy? Rev Rhum 64:183S–185S

    CAS  Google Scholar 

  29. Michels H (2000) What is low-dose corticosteroid therapy in juvenile idiopathic arthritis? Z Rheumatol 59(suppl 2):II/127–II/130

    CAS  Google Scholar 

  30. Michels H, Truckenbrodt H (1987) Improved prognosis for iridocyclitis in juvenile chronic arthritis. Clin Exp Rheum 5(suppl):20

    Google Scholar 

  31. Miller III JJ (1980) Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 65:989–994

    PubMed  Google Scholar 

  32. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 129:750–754

    Article  PubMed  CAS  Google Scholar 

  33. Oppermann J (1999) Literaturübersicht über Erfahrungen mit Ciclosporin in der Kinderrheumatologie. In: Ciclosporin in der Kinderrheumatologie. 2. Wörlitzer Expertengespräche. Wörlitz bei Dessau, 17./18. April 1999. 14.–16. April 1999, Nürnberg, Novartis Pharma GmbH. Ref Type: Conference Proceeding

    Google Scholar 

  34. Oppermann J (2000) Therapie rheumatischer Erkrankungen im Kindesalter. Innorvatis 1:18–24

    Google Scholar 

  35. Prieur AM (1996) Intravenous immunoglobulins in Still’s disease: still controversial, still unproven. J Rheumatol 23:797–800

    PubMed  CAS  Google Scholar 

  36. Ravelli A, De Benedetti F, Viola S, Martini A (1996) Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 128:275–278

    Article  PubMed  CAS  Google Scholar 

  37. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, Bernstein BH (1997) Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 24:2436–2443

    PubMed  CAS  Google Scholar 

  38. Schlote T, Dannecker G, Thiel HJ, Zierhut M (1996) Cyclosporin A in der Therapie der chronischen Uveitis im Kindesalter. Ophthalmologe 93:745–748

    Article  PubMed  CAS  Google Scholar 

  39. Silverman ED, Cawkwell GD, Lovell DJ, Laxer RM, Lehmann TJ, Passo MH, Zemel LS, Giannini EH (1994) Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 21:2353–2358

    PubMed  CAS  Google Scholar 

  40. Suschke HJ (1992) Die Behandlung der juvenilen Spondylarthritis und der reaktiven Arthritis mit Sulfasalazin. Monatsschr Kinderheilk 140:658–660

    CAS  Google Scholar 

  41. Uziel Y, Laxer RM, Schneider R, Silverman ED (1996) Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a followup study. J Rheumatol 5:910–918

    Google Scholar 

  42. van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, van Juijk WH, van Soesbergen RM, Wulffraat NM, Oostveen JC, Kuis W, Dijkstra PF, van Ede CF, Dijkmans BA (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41:808–816

    Article  PubMed  Google Scholar 

  43. Vinje O, Obiora E, Forre O (2000) Juvenile chronic polyarthritis treated with infliximab. Ann Rheum Dis 59:745

    Google Scholar 

  44. Wulffraat NM, Brinkman D, Prieur AM (2000) Autologous stem cell transplantation for refractory juvenile idiopathic arthritis. Z Rheumatol 59(suppl 3):13

    Google Scholar 

Literatur

  1. Amor B, Dougados M, Khan MA (1955) Management of refractory ankylosing spondylitis and related spondylarthropathies. Rheum Dis Clin North Am 21: 117–128

    Google Scholar 

  2. Amor B, Santos RS, Nahal R, Listrat V, Dougados M (1994) Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 21:1883–1887

    PubMed  CAS  Google Scholar 

  3. Braun J, Bollow M, Seyrebasan F, Häberle HJ, Eggens U, Mertz A, Distler A, Sieper J (1996) Computed tomography corticosteroid injection of the sacroiliac joint in the patients with spondylarthropathy with sacroiliitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 23:659–664

    PubMed  CAS  Google Scholar 

  4. Dougados M, van der Linden S, Leirisalo Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618–627

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Bosi Ferraz M, Tugwell P, Goldsmith CH, Atra E (1990) Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17:1482–1486

    Google Scholar 

  2. Carette S, Graham DC, Little H (1993) The natural disease course of ankylosing spondylitis. Arthritis Rheum 26:186–190

    Article  Google Scholar 

  3. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291

    PubMed  CAS  Google Scholar 

  4. Nissilä M, Lehtinen K, Leirisalo Repo M, Luukkainen R, Mutru O, Yli Kerttula U (1988) Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 31:1111–1116

    Article  PubMed  Google Scholar 

  5. van der Heijde D, Calin A, Dougados M, Khan MA, van der LS, Bellamy N (1999) Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical rescord keeping in ankylosing spondylitis. Progress report of the ASAS Working Group, Assessments in Ankylosing Spondylitis. J Rheumatol 26: 951–954

    PubMed  Google Scholar 

  6. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York Criteria. Arthritis Rheum 361–368

    Google Scholar 

Literatur

  1. Brückle W, Dexel T, Grasedyck K, Schattenkirchner M (1994) Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate. Clin Rheumatol 13: 209–216

    PubMed  Google Scholar 

  2. Cuellar MI, Silveira LH, Espinoza LR (1994) Recent developments in psoriatic arthritis. Curr Opin Rheumatol 6:378–384

    PubMed  CAS  Google Scholar 

  3. Dougados M, van der Linden S, Leirisalo-Repo M (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, doubleblind-placebo-controlled study. Arthr Rheum 38:618–627

    Article  CAS  Google Scholar 

  4. Gladman DD, Blake R, Brubacher B, Farewell VT (1992) Chloroquine therapy in psoriatic arthritis. J Rheumatol 19:1724–1726

    PubMed  CAS  Google Scholar 

  5. Goupille P, Soutif D, Valant JP (1992) Treatment of psoriatic arthropathy. Sem Arthr Rheum 21:355–367

    Article  CAS  Google Scholar 

  6. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50:1939–1950

    Article  PubMed  CAS  Google Scholar 

  7. Lehmann P, Ruzicka T (1996) Neue Entwicklungen in der Psoriasistherapie. Dtsch Ärztebl 93:A-3188–3193

    Google Scholar 

  8. Mease PJ, Goffe BS, Metz J, Van der Stoep A, Fink B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385–390

    Article  PubMed  CAS  Google Scholar 

  9. Antoni C, Kavanaugh A, Kirkham B et al (2002) The Infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 46:381

    Google Scholar 

  10. Pigatto PD, Gibelli E, Ranza R, Rossetti A (1994) Methotrexate in psoriatic polyarthritis. Acta Derm Venerol (suppl) (Stockh) 186:114–115

    CAS  Google Scholar 

  11. Steinsson K, Jonsdottier I, Valdimarsson H (1990) Ciclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 49:603–606

    Article  PubMed  CAS  Google Scholar 

  12. Stroehmann I, Wüstenhagen E, Martini M (1987) Die Therapie seronegativer Oligoarthritiden mit Salazopyrin. Z Rheumatol 46:21–24

    Google Scholar 

  13. Willkens RF, Williams HJ, Ward JR (1984) Randomized double-blind placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthr Rheum 27:376–381

    Article  CAS  Google Scholar 

Literatur

  1. Bardin T, Enel C, Cornelis F, Salski C, Jorgensen C, Ward R, Lathrop GM (1992) Antibiotic treatment of venereal disease and Reiter’s syndrome in a Greenland population. Arthritis Rheum 35:190–194

    Article  PubMed  CAS  Google Scholar 

  2. Braun J, Eggens U, Sieper J (1994) Grundlagen der Therapie der reaktiven Arthritis. Wien Klin Wochenschr 106:259–264

    PubMed  CAS  Google Scholar 

  3. Fryden A, Bengtsson A, Foberg U, Svenungsson B, Castor B, Kärnell A, Schvarcz R, Lindblom B, Kihlström E (1990) Early antibiotic treatment of reactive arthritis associated with enteric infection. Clinical and serological study. Br Med J 301: 1229–130

    Google Scholar 

  4. Hammer M, Wollenhaupt J (1994) Reaktive Arthritiden. In: Gerok W, Hartmann F, Pfreundschuh M, Philipp T, Schuster H-P, Sybrecht GW (Hrsg) Klinik der Gegenwart, XIV,3. Urban und Schwarzenberg, München Wien Baltimore, S 1–48

    Google Scholar 

  5. Lauhio A, Leirisalo-Repo M, Lähdevita J, Saikku P, Repo H (1991) Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 34:6–14

    Article  PubMed  CAS  Google Scholar 

  6. Mielants H, Veys EM (1985) HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine in HLA-B27-realted reactive arthritis. J Rheumatol 12:287–293

    PubMed  CAS  Google Scholar 

  7. Pott HG, Wittenborg A, Junge-Hülsing G (1988) Long-term antibiotic treatment in reactive arthritis. Lancet i:245–246

    Article  Google Scholar 

  8. Sieper J, Braun J (1993) Möglichkeiten und Grenzen der Diagnostik bei der reaktiven Arthritis. Dtsch Med Wschr 118:712–718

    Article  PubMed  CAS  Google Scholar 

  9. Sieper J, Braun J, Reichardt M, Eggens U (1993) The value of specific antibody detection and culture in the diagnosis of reactive arthritis. Clin Rheumatol 12:245–252

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Cilliers AM (2006) Rheumatic fever and its management. BMJ 333:1153–1156

    Article  PubMed  Google Scholar 

  2. Carapetis JR, McDonald M, Wilson NJ (2005) Acute rheumatic fever. Lancet 366: 155–168

    Article  PubMed  Google Scholar 

  3. Keitzer R (2005) Acute rheumatic fever (ARF) and poststreptococcal reactive arthritis (PSRA) — an update. Z Rheumatol 64:295–307

    Article  PubMed  CAS  Google Scholar 

  4. Robertson KA, Volmink JA, Mayosi BM (2005) Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord 5:11

    Article  PubMed  Google Scholar 

  5. Gibofsky A, Zabriskie JB (1995) Rheumatic fever and poststreptococcal reactive arthritis. Curr Opin Rheumatol 7:299–305

    Article  PubMed  CAS  Google Scholar 

  6. Berrios X, del Campo E, Guzman B, Bisno AL (1993) Discontinuing rheumatic fever prophylaxis in selected adolescents and young adults. A prospective study. Ann Intern Med 401–406

    Google Scholar 

Literatur

  1. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ (1988) Treatment of late Lyme borreliosis: randomized comparison of ceftriaxone and penicillin. Lancet I:1191–1194

    Article  Google Scholar 

  2. Herzer P (1993) Therapy of joint manifestations. In: Weber K, Burgdorfer W (eds) Aspects of Lyme borreliosis. Springer, Berlin Heidelberg New York, pp 340–343

    Google Scholar 

  3. Schoen RT, Aversa JM, Rahn DW, Steere AC (1991) Treatment of refractory chronic Lyme arthritis with arthroscopic synovectomy. Arthritis Rheum 34:1056–1060

    Article  PubMed  CAS  Google Scholar 

  4. Steere AC, Greene J, Schoen RT, Taylor E, Hutchinson GJ, Rahn DW, Malawista SE (1985) Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med 312:869–874

    Article  PubMed  CAS  Google Scholar 

  5. Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JA III, Liu NY, Schmid CH (1994) Treatment of Lyme arthritis. Arthritis Rheum 37:878–888

    Article  PubMed  CAS  Google Scholar 

  6. Wormser GP, Nadelman RB, Dattwyler RJ et al (2000) Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 31(suppl 1):S1–S14

    Article  CAS  Google Scholar 

Literatur

  1. Fox R (2003) Sjögren’s syndrome: evolving therapies. Expert Opin Investig Drugs 12:247–254

    PubMed  CAS  Google Scholar 

  2. Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjögren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5(suppl 1):31–36

    Google Scholar 

  3. Khurshudian AV (2003) A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95:38–44

    PubMed  Google Scholar 

  4. Petrone D, Condemi JJ, Fife R et al (2002) A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis. Arthritis Rheum 46:748–754

    Article  PubMed  CAS  Google Scholar 

  5. Steinfeld SD, Demols P, Salmon et al (2001) Infliximab in patients with primary Sjögren’s syndrome: a pilot study. Arthritis Rheum 44:2371–2375

    Article  PubMed  CAS  Google Scholar 

  6. Steinfeld SD, Demols P, Appelboom T (2002) Infliximab in primary Sjögren’s syndrome: one-year followup. Arthritis Rheum 46:3301–3303

    Article  PubMed  CAS  Google Scholar 

  7. Vivino FB, Al-Hashimi I, Khan Z et al (1999) Pilocarpine tablets for the treatment of dry mouth and drey eye syndroms in patients with Sjögren syndrome: a randomized placebo-controlled, fixed-dose, multicenter trial. P992-01 Study Group. Arch Int Med 159:174–181

    Article  CAS  Google Scholar 

Literatur

  1. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B (2003) LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a rondomized, doubleblind, placebo-controlled study. Arthritis Rheum 48:442–454

    Article  PubMed  CAS  Google Scholar 

  2. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745

    Article  PubMed  CAS  Google Scholar 

  3. Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150–154

    Article  Google Scholar 

  4. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162

    Article  PubMed  CAS  Google Scholar 

  5. Derksen RHWM, de Groot PhG, Kater L, Nieuwenhuis HK (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive longterm anticoagulant treatment. Ann Rheum Dis 52:689–692

    PubMed  CAS  Google Scholar 

  6. Francioni C, Galeazzi M, Fioravanti A, Gelli R, Megale F, Marcolongo R (1994) Long term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 12:163–168

    PubMed  CAS  Google Scholar 

  7. Ginzler EM, Felson DT, Anthony JM, Anderson JJ (1993) Hypertension increases the risk of renal deterioration in systemic lupus erythematosus. J Rheumatol 20:1694–1700

    PubMed  CAS  Google Scholar 

  8. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997

    Article  PubMed  CAS  Google Scholar 

  9. Kimberley W, Abeles M (1994) A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 21:1674–1677

    Google Scholar 

  10. Klippel JH (1990) Systemic lupus erythematosus. Treatment-related complications superimposed on chronic disease. JAMA 263:1812–1815

    Article  PubMed  CAS  Google Scholar 

  11. Steinberg AD, Gourley MF, Klinman DM, Tsokos GC, Scott DE, Krieg A (1991) Systemic lupus erythematosus. Ann Intern Med 115:548–559

    PubMed  CAS  Google Scholar 

  12. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945–950

    Article  PubMed  CAS  Google Scholar 

  13. Sztejnbok M, Stewart A, Diamond H, Kaplan D (1971) Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum 14:639–645

    Article  PubMed  CAS  Google Scholar 

  14. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J (1994) Effect of low-dose Ciclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 37:551–558

    Article  PubMed  CAS  Google Scholar 

  15. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:221–225

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Alarcon-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M, Shoenfeld Y, Wilson W, Roubey R (2003) Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus 12:499–503

    Article  PubMed  CAS  Google Scholar 

  2. Ames PR, Khamashta MA, Hughes GR (1995) Clinical and therapeutic aspects of the antiphospholipid syndrome. Lupus. 4(suppl 1):S23–S25

    PubMed  Google Scholar 

  3. Barbui T, Finazzi G (1994) Clinical trials on antiphospholipid syndrome: what is being done and what is needed? Lupus 3:303–307

    Article  PubMed  CAS  Google Scholar 

  4. Bermas BL, Schur PH, Kaplan AA (2006) In: Rose BD (ed) Treatment of the antiphospholipid syndrome. Uptodate 10/2006, USA

    Google Scholar 

  5. Cohen MG, Lui SF (1992) Multiple complications of the antiphospholipid syndrome with apparent response to aspirin therapy. J Rheumatol 19:803–806

    PubMed  CAS  Google Scholar 

  6. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD (2001) High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 44:1466–1467

    Article  PubMed  CAS  Google Scholar 

  7. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E et al (1996) Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a fouryear prospective study from the Italian Registry. Am J Med 100:530–536

    Article  PubMed  CAS  Google Scholar 

  8. Fischer-Betz R, Specker C (2003) Antiphospholipid-Antikörper und Schwangerschaft. Akt Rheumatol 28:131–137

    Article  Google Scholar 

  9. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer MJ (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117:997–1002

    PubMed  CAS  Google Scholar 

  10. Hughes GR (1993) The antiphospholipid syndrome: ten years on. Lancet 342:341–344

    Article  PubMed  CAS  Google Scholar 

  11. Khamashta MA (1996) Management of thrombosis in the antiphospholipid syndrome. Lupus 5:463–466

    PubMed  CAS  Google Scholar 

  12. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997

    Article  PubMed  CAS  Google Scholar 

  13. Petri M (1997) Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am 81:151–177

    Article  PubMed  CAS  Google Scholar 

  14. Petri M, Qazi U (2006) Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am 32:591–607

    Article  PubMed  Google Scholar 

  15. Piette JC (1996) 1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a „mission impossible“? Lupus 5:354–363

    PubMed  CAS  Google Scholar 

  16. Rosove MH, Brewer PM (1992) Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117:303–308

    PubMed  CAS  Google Scholar 

  17. Roubey RA (2002) Treatment of the antiphospholipid syndrome. Curr Opin Rheumatol 14:238–242

    Article  PubMed  CAS  Google Scholar 

  18. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR (2002) Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 162:1164–1169

    Article  PubMed  Google Scholar 

  19. Specker C (2002) Inzidenz thromboembolischer Komplikationen beim APS. Das Antiphospholipidsyndrom — Bedeutung der Antiphospholipid-Antikörper für Diagnose, Differentialdiagnose, Prognose und Therapie des systemischen Lupus Erythematodes. Habilitationsschrift, Kap. 1.4.5. Shaker, Aachen, S 18–19

    Google Scholar 

  20. Specker C, Rademacher J, Sohngen D, Sitzer M, Janda I, Siebler M, Steinmetz H, Schneider M (1997) Cerebral microemboli in patients with antiphospholipid syndrome. Lupus 6:638–644

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729

    Article  PubMed  CAS  Google Scholar 

  2. Albrecht HP, Hiller D, Hornstein OP, Buhler-Singer S, Muck M, Gruschwitz M (1993) Microcirculatory functions in systemic sclerosis: additional parameters for therapeutic concepts? J Invest Dermatol 1001:211–215

    Article  Google Scholar 

  3. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wi FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill M, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425–434

    PubMed  CAS  Google Scholar 

  4. Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N (1999) Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud’s phenomenon. Minerva Cardioangiol 47:137–143

    PubMed  CAS  Google Scholar 

  5. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, Finke J, Peter HH, van Laar J, Breedveld FC, Fibbe WE, Farge D, Gluckman E, Locatelli F, Martini A, van den Hoogen F, van de Putte L, Schattenberg AV, Arnold R, Bacon PA, Emery P, Espigado I, Hertenstein B, Hiepe F, Kashyap A, Kotter I, Marmont A, Martinez Pascula MJ, Gratwohl A, Prentice HG, Black C, Tyndall A (2001) Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and on skin disease. Ann Rheum Dis 60:577–584

    Article  PubMed  CAS  Google Scholar 

  6. Black CM, Denton CP (1995) The management of systemic sclerosis. Br J Rheumatol 34:3–7

    Article  PubMed  CAS  Google Scholar 

  7. Channik RN, Simmoneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainiso M, Bodin F, Rubin LJ (2001) Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123

    Article  Google Scholar 

  8. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, Weisman MH, Barr W, Moreland LW, Medsger TA Jr, Steen V, Ma RW, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold JR (1999) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42:1194–1203

    Article  PubMed  CAS  Google Scholar 

  9. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, Paulus HE (1993) Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36:75–83

    Article  PubMed  CAS  Google Scholar 

  10. Cribier B, Faradji T, Le Coz C, Oberling F, Grosshans E (1995) Extracorporal photochemotherapy in systemic sclerosis and severe morphea. Dermatology 191:25–31

    Article  PubMed  CAS  Google Scholar 

  11. Descamps V, Duval X, Crickx B, Bouscarat F, Coffin B, Belaich S (1999) Global improvement of systemic scleroderma under long-term administration of octreotide. Eur J Dermatol 9:446–448

    PubMed  CAS  Google Scholar 

  12. Di Spaltro FX, Cotrill C, Cahill C, Degnan E, Mulford GJ, Scarborough D, Franks AJ Jr, Klainer ASS, Biasaccia E (1993) Extracorporeal photochemotherapy in progressive systemic sclerosis. Int J Dermatol 32:417–421

    Article  PubMed  Google Scholar 

  13. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM (1999) Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen week randomized, parallel-group, controlled trial. Arthritis Rheum 42:2646–2655

    Article  PubMed  CAS  Google Scholar 

  14. Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema de Rie MA, Schellekens PT, ten Berge IJ, de Borgie CA, Bos JD (1999) Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 41:915–922

    Article  PubMed  CAS  Google Scholar 

  15. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, Hachulla E, Phillipe P, Sibilia J, Rabian C, Chevret S, Gluckman E, Intensification of Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group (2002) Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I–II study. Br J Haematol 119:726–739

    Article  PubMed  Google Scholar 

  16. Furst DE, Clements PJ (2001) D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol 30:189–191

    Article  PubMed  CAS  Google Scholar 

  17. Genth E (2001) Evidenz-basierte Therapie der systemischen Sklerose. Z Rheumatol 60:464–468

    Article  PubMed  CAS  Google Scholar 

  18. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML, Fulminis A, De Luca A, Farina G, Candela M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri S, Gabrielli A, Tonietti G, Cerinic MM (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731–736

    PubMed  CAS  Google Scholar 

  19. Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jabkowski J, MacHeiner W, Salmhofer W, Zahel B, Pinter G, Herold M, Klein G, Fritsch PO (1998) Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 139:639–648

    Article  PubMed  CAS  Google Scholar 

  20. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and intestitial lung disease: a pilot study using intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography and lung function. J Rheumatol 29:2371–2378

    PubMed  CAS  Google Scholar 

  21. Jansen GT, Barraza DF, Steen VD (1968) Generalized scleroderma: treatment with a immunosupressive agent. Arch Dermatol 97:690–698

    Article  PubMed  CAS  Google Scholar 

  22. Jimenez SA, Sigal SH (1991) A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 18:1496–1503

    PubMed  CAS  Google Scholar 

  23. Lecomte T, Cavicchi M, Delchier JC (2000) Small bowel pseudo-obstruction revealing in early scleroderma. Long-term efficacy of octreotide and erythromycin. Gastroenterol Clin Biol 24:361–363

    PubMed  CAS  Google Scholar 

  24. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE (2002) High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 100:1602–1610

    PubMed  CAS  Google Scholar 

  25. Medsger TA Jr, Lucas M, Wildy KS, Baker C (2001) D-penicillamine in systemic sclerosis? Yes! Scand J Rheumatol 30:192–194

    Article  PubMed  Google Scholar 

  26. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 29:298–304

    PubMed  CAS  Google Scholar 

  27. Parameswaran K, Purcell I, Farrer M, Holland C, Taylor IK, Keaney MP (1999) Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis. Respir Med 93:75–78

    Article  PubMed  CAS  Google Scholar 

  28. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev (2):CD000953

    Google Scholar 

  29. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev (2):CD000956

    Google Scholar 

  30. Rook AH, Freundlich B, Jegasothy BV, Perze MI, Barr WG, Jimenez SA, Rietschel RL, Wintroub B, Kahaleh MB, Varga J (1992) Treatment of systemic sclerosis with extracorporeal photochemotherapy: results of a multicenter trial. Arch Dermatol 128:337–346

    Article  PubMed  CAS  Google Scholar 

  31. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary hypertension. N Engl J Med 346:896–903

    Article  PubMed  CAS  Google Scholar 

  32. Russell ML, Schachter RK (1988) Cyclosporin treatment of scleroderma (PSS). Arthritis Rheum 31:S51

    Google Scholar 

  33. Schnabel A, Reuter M, Gross WL (1998) Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 41:1215

    Article  PubMed  CAS  Google Scholar 

  34. Sharada B, Kumar A, Kakker R, Adya CM, Pande I, Uppal SS, Pande JN, Sunderam KR, Malaviya AN (1994) Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int 14:91–94

    Article  PubMed  CAS  Google Scholar 

  35. Shor R, Halabe A (2002) New trends in the treatment of scleroderma renal crisis. Nephron 92:716–718

    Article  PubMed  CAS  Google Scholar 

  36. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Erikson M, Hannigan J, Harkonen WS, Sanders ME (2000) Recombinant human relaxin in the treatment of scleroderma. A randomized, placebo-controlled trial. Ann Intern Med 132:871–879

    PubMed  CAS  Google Scholar 

  37. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Stange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844

    PubMed  CAS  Google Scholar 

  38. Steen VD, Medsger TA Jr, Rodnan DP (1982) D-penicillamine therapy in progressive systemic sclerosis (scleroderma). An Intern Med 97:652–658

    CAS  Google Scholar 

  39. Steen VD, Lanz JK, Conte C, Owens GR, Medsger TA Jr (1998) Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 37:1290–1296

    Article  Google Scholar 

  40. Sturgill MG, Seibold JR (1998) Rational use of calcium-channel antagonists in Raynaud’s phenomenon. Curr Opin Rheumatol 10:584–588

    Article  PubMed  CAS  Google Scholar 

  41. Tyndall A, Koike T (2002) High-dose immunoablative therapy with hematopoietic stem cell support in the treatment of severe autoimmune disease: current status and future direction. Intern Med 41:608–612

    Article  PubMed  Google Scholar 

  42. Uhlemann C (1993) Physiotherapie der Kollagenosen mit besonderer Berücksichtigung der Sklerodermie. Z Hautkr 68:678–683

    Google Scholar 

  43. Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB (1996) Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial followed by a 24 week observational trial. Br J Rheumatol 35:364–372

    Article  PubMed  Google Scholar 

  44. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, Steen VD, Jimenez S, Mayes M (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebocontrolled, double-blind study. Ann Intern Med 120:19–206

    Google Scholar 

  45. Wollersheim H, Thein T, van’t Laar A (1987) Nifedipine in primary Raynaud’s phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. J Clin Pharmacol 27:907–913

    PubMed  CAS  Google Scholar 

  46. Zachariae H, Bjerring P, Heickendorff L, Moller B, Wallervik K, Angelo H (1993) Photopheresis in systemic sclerosis: clinical and serological studies using markers of collagen metabolism. Acta Derm Venereol (Stockh) 73:356–361

    PubMed  CAS  Google Scholar 

Literatur

  1. Alexanderson H (2005) Exercise: an important component of treatment in the idiopathic inflammatory myopathies. Curr Rheumatol Rep 7:115–124

    Article  PubMed  Google Scholar 

  2. Baer AN (2006) Advances in the therapy of idiopathic inflammatory myopathies. Curr Opin Rheumatol 18:236–241

    Article  PubMed  CAS  Google Scholar 

  3. Cherin P, Herson S, Wechsler B, Piette JC, Godeau P (1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis. Am J Med 91:162–168

    Article  PubMed  CAS  Google Scholar 

  4. Choy EH, Hoogendijk JE, Lecky B, Winer JB (2005) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 20; CD003643

    Google Scholar 

  5. Dalakas MC, Illa I, Dambrosia JM, Soulidan SA, Stein DP, McCrosky S (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. New Engl J Med 329:1993–2000

    Article  PubMed  CAS  Google Scholar 

  6. Gran JM, Herrero C, Urbano-Marquez A (1994) Cyclosporin A as first choice therapy for dermatomyositis. J Rheumato 121:381–382

    Google Scholar 

  7. Keen RW, Gumpel JM (1993) Cyclosporin A in adult dermatomyositis. Brit J Rheumatol 32:439

    Article  CAS  Google Scholar 

  8. Medsger TA, Oddis CV (1995) Classification and diagnostic criteria for polymyositis and dermatomyositis. J Rheumatol 22:581–585

    PubMed  Google Scholar 

  9. Miller LC, Sisson BA, Tucker LB, Schaller JG (1992) Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthr Rheum 35:1143–1149

    Article  CAS  Google Scholar 

Literatur

  1. Cohen MD, Ginsburg WW (1990) Polymyalgia rheumatica. Rheum Dis Clin North Am 16:325–329

    PubMed  CAS  Google Scholar 

  2. Gabriel SE, Sunku J, Salvarani C et al (1997) Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40: 1873–1878

    Article  PubMed  CAS  Google Scholar 

  3. Hunder GG (1990) Giant cell aarteritis. Rheum Dis Clin North Am 16:399–409

    PubMed  CAS  Google Scholar 

  4. Jover JA, Hernandez-Garcia C, Morado IC et al (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. Ann Intern Med 134: 106–114

    PubMed  CAS  Google Scholar 

  5. Kaiser H, Kley HK (1992) Cortisontherapie (9. Aufl). Urban & Schwarzenberg, München

    Google Scholar 

  6. Langford CA, Sneller MC (2003) Biologic therapies in the vasculitides. Curr Opin Rheumatol 15:3–10

    Article  PubMed  Google Scholar 

  7. Levine MS, Hellman DB (2002) Giant cell arteritis. Curr Opin Rheumatol 14:3–10

    Article  PubMed  Google Scholar 

  8. Richter C, Schnabel A (2000) Riesenzell-(Temporal-)Arteriitis (GCA) und Takayasu-Arteriitis (TA). In: Gross WL (Hrsg) Therapie der Immunvaskulitiden. UNIMED-Verlag, Bremen, S 64–65

    Google Scholar 

  9. Wollenhaupt J (2003) Gerontorheumatologie. Thieme, Stuttgart, S 22–30

    Google Scholar 

Literatur

  1. Daina E, Schieppati A, Remuzzi G (1999) Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 130:422–426

    PubMed  CAS  Google Scholar 

  2. Hoffmann GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthr Rheum 37:578–582

    Article  Google Scholar 

  3. Kerr G, Hallahan C, Leavitt R, Fauci A, Hoffmenn G (1993) A study of 60 patients with Takayasús arteritis: presentation, treatment and long-term outcome. Arthr Rheum 36(suppl):R5

    Google Scholar 

  4. Ohtecki H, Itoh T, Natsuaki M, Minato N, Ueno T, Suda H, Naito K, Norita H, Sakai H (1992) Aortic valve replacement for Takayasús arteritis. J. Thorac Cardiovasc Surg 104: 82–486

    Google Scholar 

  5. Richter C, Schnabel A (2000) Riesenzell-(Temporal-)Arteriitis (GCA) und Takayasu-Arteriitis (TA). In: Gross WL (Hrsg) Therapie der Immunvaskulitiden. UNIMED-Verlag, Bremen, S 65–66

    Google Scholar 

  6. Sharma S, Saxena A, Talwar KK, Kaul U, Mehta SN, Rajani M (1992) Renal artery stenosis caused by nonspecific arteritis (Takayasu disease): Results of treatment with percutaneous transluminal angioplasty. Am J Roentgenol 158:417–422

    CAS  Google Scholar 

Literatur

  1. Carson CW, Conn DL, Czaja AJ, Wright TL, Brecher ME (1993) Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 20:304–309

    PubMed  CAS  Google Scholar 

  2. Durand JM, Kaplanski G, Fefevre P et al (1992) Effect of Interferon alpha 2b on cryoglobulinemia related to hepatitis C virus infection. J Infect Dis 165:778–779

    PubMed  CAS  Google Scholar 

  3. Guillevin L, Fain O, Lhote F, Jarrousse B, Le Thi Huong Du D, Bussel A, Leon A (1992) Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss Syndrome. Arthritis Rheum 35:208–215

    Article  PubMed  CAS  Google Scholar 

  4. Guillevin L, Jarousse B, Lok C, Lhote F, Jais JP, Le Thi Huong Du D, Bussel A (1991) Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. J Rheumatol 18:567–574

    PubMed  CAS  Google Scholar 

  5. Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C (1993) Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 20:289–298

    PubMed  CAS  Google Scholar 

  6. Guillevin L, Lhote F, Cohen P et al (1995) Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 74:238–253

    Article  PubMed  CAS  Google Scholar 

  7. Jenette JC, Falk RJ, Andrassy K, Bacon A, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CGM, McCluskey RT, Sinicio RA, Rees AJ, van Es LA, Waldherr R, Wiik A (1994) Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthr Rheum 37:187–192

    Article  Google Scholar 

  8. Lamprecht P, Gause A, Gross WL (1999) Cryoglobulinemic vasculitis. Arthritis Rheum 42:2507–2516

    Article  PubMed  CAS  Google Scholar 

  9. Lightfood RW, Michel BA, Bloch DA, Hunder GG, Zwaifler NJ, McShane DJ, Arend WP, Calabrese LH, Leavitt RY, Lie JT, Masi AT, Mills JA, Stevens MB, Wallace SL (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthr Rheum 33:1088–1093

    Article  Google Scholar 

  10. Quint L, Deny P, Guillevin L, Granger B, Jarrousse B, Lhote F, Scavizzi M (1991) Hepatitis C virus in patients with polyarteritis nodosa. Prevalence in 38 patients. Clin Exp Rheumatol 9:253–257

    PubMed  CAS  Google Scholar 

  11. Reichard O, Norkrans G, Fryden A, Braconier J-H, Sönnerborg A, Weiland O (1998) Randomised, double-blind, placebo-controlled trial of interferon a-2b with and without ribavirin for chronic hepatitis C. Lancet 351:83–87

    Article  PubMed  CAS  Google Scholar 

  12. Trepo C, Guillevin L (2001) Polyarteriitis nodosa and extrahepatic manifestations of HBV infection: The case against autoimmune intervention in pathogenesis. J Autoimmunol 16:269–274

    Article  CAS  Google Scholar 

Literatur

  1. Burns JC (2001) Kawasaki disease. Adv Pediatr 48:157–177

    PubMed  CAS  Google Scholar 

  2. Nakamura Y, Fujita Y, Nagai M, Yanagawa H, Imada Y, Okawa S, Kawasaki T, Kato H (1991) Cardiac sequelae of Kawasaki disease in Japan: statistical analysis. Pediatrics 88:1144–1147

    PubMed  CAS  Google Scholar 

  3. American Academy of Pediatrics (1988) Intravenous gamma-globulin use in children with Kawasaki disease. Pediatrics 82:122–123

    Google Scholar 

  4. Rowley AH, Shulman ST (1991) Current therapy for acute Kawasaki syndrome. J Pediatr 118:987–991

    Article  PubMed  CAS  Google Scholar 

  5. Sundel RP (2002) Update on the treatment of Kawasaki disease in childhood. Curr Rheumatol Rep 4:474–482

    Article  PubMed  Google Scholar 

  6. Wallace CA, French JW, Kahn SJ, Sherry DD (2000) Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 105:E78

    Article  PubMed  CAS  Google Scholar 

  7. Fukushige J (1994) Incidence and clinical features of incomplete Kawasaki disease. Acta Paediat 83:1057–1060

    Article  PubMed  CAS  Google Scholar 

  8. Shinohara M, Sone K, Tomomasa T, Morikawa A (1999) Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 135:465–469

    Article  PubMed  CAS  Google Scholar 

  9. Wright DA, Newburger JW, Baker A, Sundel RP (1996) Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 128:146–149

    Article  PubMed  CAS  Google Scholar 

  10. Kato H, Koike S, Yokoyama T (1979) Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 63:175–179

    PubMed  CAS  Google Scholar 

  11. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96:1057–1061

    PubMed  CAS  Google Scholar 

  12. Leung DYM (1993) Kawasaki disease. Curr Opin Rheumatol 5:41–50

    Article  PubMed  CAS  Google Scholar 

  13. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, Colan SD, Duffy CE, Fulton DR, Glode MP, Mason WH, Meissner C, Rowley AH, Shulman ST, Reddy V, Sundel RP, Wiggins JW, Colton T, Melish ME, Rosen F (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639

    Article  PubMed  CAS  Google Scholar 

  14. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW (1993) Gamma globulin re-treatment in Kawasaki disease. J Pediatr 123:657–659

    Article  PubMed  CAS  Google Scholar 

  15. Takahashi M (1997) Kawasaki disease. Curr Opin Pediatr 9:523–529

    Article  PubMed  CAS  Google Scholar 

  16. Dajanai AS, Taubert KA, Gerber MA, Shulman ST, Ferrierei P, Freed M, Takahashi M, Bierman FZ, Karchmer AW, Wilson W et al (1993) Diagnosis and therapy of Kawasaki disease in children. Circulation 87:1776–1780

    Google Scholar 

  17. Marasini M, Pongiglione G, Gazzolo D, Campelli A, Ribaldone D, Caponnetto S (1991) Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol 68:796–797

    Article  PubMed  CAS  Google Scholar 

  18. Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD (1994) Intravenous immunoglobulin-induced osmotic nephrosis. Arch Int Med 154:1985–1987

    Article  CAS  Google Scholar 

  19. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 331:1607–1611

    Article  PubMed  CAS  Google Scholar 

  20. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ, Jonas MM, Yu MY, Renzi PM, Schneider LC (1996) Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 276:1563–1567

    Article  PubMed  CAS  Google Scholar 

  21. Cremer H (2002) Kawasaki-Syndrom — ein Update. Akt Rheumatol 27:270

    Google Scholar 

  22. Petty RE, Cassidy JT (2001) Kawasaki disease. In: Cassidy JT, Petty RE (eds) Textbook of pediatric rheumatology. WB Saunders Company, Philadelphia, pp 580–594

    Google Scholar 

  23. Koren G, Silverman E, Sundel R, Edney P, Newburger JW, Klein J, Robieux I, Laxer R, Giesbrecht E, Burns JC (1991) Decreased protein binding of salicylates in Kawasaki disease. J Pediatr 118:456–459

    Article  PubMed  CAS  Google Scholar 

  24. Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K (1994) Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr 153:663–667

    Article  PubMed  CAS  Google Scholar 

  25. Checcia PA, Pahl E, Shaddy RE, Shulman ST (1997) Cardiac transplantation for Kawasaki disease. Pediatrics 100:695–699

    Article  Google Scholar 

Literatur

  1. De Groot K, Gross WL, Herlyn K, Reinhold-Keller E (2001) Development and validation of a disease extent index for ANCA-associated vasculitides. Clin Nephrol 55:31–38

    PubMed  Google Scholar 

  2. De Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL (1998) Induction of remission in Wegener’s granulomatosis with low-dose methotrexate. J Rheumatol 25:492–495

    PubMed  Google Scholar 

  3. De Groot K, Adu D, Savage CO (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis. Meta-analysis and critical review. Nephrol Dial Transplant 16(10):2018–2027

    Article  PubMed  Google Scholar 

  4. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Banbury P, Gordon C, Savage COS, Adu D (1997) Development and initial validation of the Vasculitis Damage Index (VDI) for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371–380

    Article  PubMed  CAS  Google Scholar 

  5. Gross WL (2002) Churg Strauss syndrome: update on recent developments. Curr Opin Rheumatol 14:11–14

    Article  PubMed  CAS  Google Scholar 

  6. Gross WL (1999) New concepts in treatment protocols for severe systemic vasculitis. Curr Opin Rheumatol 11:41–46

    Article  PubMed  CAS  Google Scholar 

  7. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener’ granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498

    PubMed  CAS  Google Scholar 

  8. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Sesavre P, Jacquot C, Bindie P, Bielefeld P, Desson JF et al (1997) A prospective multicenter, randomized trial comparing steroids and pulses cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 40:2187–2198

    Article  PubMed  CAS  Google Scholar 

  9. Jayne DRW, Gaskin D, for EUVAS (1999) Randomized trial of cyclophosphamide versus azathioprine during remission in ANCA-associated vasculitis (CYCAZAREM). J Am Soc Nephrol 10:105A

    Google Scholar 

  10. Jayne DRW, Rasmussen N, for the European Community Systemic Vasculitis Clinical Trials Study Group (1997) Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community System Vasculitis Clinical Trials Study Group. Mayo Clin Proc 72:737–747

    PubMed  CAS  Google Scholar 

  11. Langford CA, Talar-Williams C, Barron KS, Sneller MC (1999) A staged approach to the treatment of Wegener’s granulomatosis. Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 42:2666–2673

    Article  PubMed  CAS  Google Scholar 

  12. Langford CA, Talar-Williams C, Sneller MC (2000) Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43:1836–1840

    Article  PubMed  CAS  Google Scholar 

  13. Luqmani RA (2002) Assessing disease activity in the systemic vasculitides. Curr Opin Rheumatol 14:23–28

    Article  PubMed  Google Scholar 

  14. Metzler C, Fink COE, Lamprecht P, Gross WL, Reinhold-Keller E (2001) Pilot Study of the Safety and Efficacy of Leflunomid (LEF) in Patients with Wegener’s Granulomatosis (WG) in Remission. Ann Rheum Dis 60(suppl 1):p 133

    Google Scholar 

  15. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ (1999) Mycophenolate mofetil for maintenance therapy of Wegeners granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 10:1965–1971

    PubMed  CAS  Google Scholar 

  16. Reinhold-Keller E, de Groot K, Rudert H, Nölle B, Heller M, Gross WL (1996) Response to trimethoprim/sulfamethoxazole in Wegener’s granulomatosis depends on the phase of disease. Q J Med 89:15–23

    CAS  Google Scholar 

  17. Reinhold-Keller E, Fink COE, Herlyn K, Gross WL, de Groot K (2002) High rate of renal relapses in 71 patients with Wegener’s granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Care Res (in press)

    Google Scholar 

  18. Reinhold-Keller E, Herlyn K (2001) Interdisziplinäre Betreuung von Vaskulitis-Patienten: Der Internist/Rheumatologe. Z Rheumatol 60:208–218

    Article  PubMed  CAS  Google Scholar 

  19. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, Heller M, Gross WL (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis. Arthritis Rheum 43:1021–1032

    Article  PubMed  CAS  Google Scholar 

  20. Richter C, Schnabel A, Csernok E, de Groot K, Reinhold-Keller E, Gross WL (1995) Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 101:2–7

    Article  PubMed  CAS  Google Scholar 

  21. Tervaert CJW, Stegemann CA, Kallenberg CG (2001) Novel therapies for antineutrophil cytoplasmic antibody associated vasculitis. Curr Opin Nephrol Hypertens 2:211–217

    Google Scholar 

Literatur

  1. Foster BJ, Bernard C, Drummond KN et al (2000) Effective therapy for severe Henoch-Schönlein purpura nephritis: a clinical and histolopathologic study. J Pediatr 136:370–375

    Article  PubMed  CAS  Google Scholar 

  2. Frank T, Saulsbury MD (2001) Henoch-Schönlein purpura. Curr Opin Rheumatol 13:35–40

    Article  Google Scholar 

  3. Mollica F, Li Volti S, Garozzo R, Russo G (1992) Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactic purpura. Eur J Pediatr 151:140–144

    Article  PubMed  CAS  Google Scholar 

  4. Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243

    Article  PubMed  CAS  Google Scholar 

  5. Schulz H, Grabbe J, Trabandt A (2000) Henoch-Schönlein Purpura and leukozytoklastische Angiitis. In: Gross WL (Hrsg) Therapie der immunvaskulitiden. UNIMED-Verlag, Bremen, S 130–132

    Google Scholar 

  6. Szer IS (1994) Henoch-Schönlein purpura. Curr Opin Rheumatol 6:25–31

    Article  PubMed  CAS  Google Scholar 

  7. Szer IS (1999) Gastrointestinal and renal involvement in vasculitis: management strategies in Henoch-Schönlein purpura. Cleve Clin J Med 66:312–317

    PubMed  CAS  Google Scholar 

Literatur

  1. Agnello V, Chung RT, Kaplan LM (1992) A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327:1490–1495

    Article  PubMed  CAS  Google Scholar 

  2. Cacoub P, Costedoat-Chalumeau N, Lidove O, Alric L (2002) Cryoglobulinemia vaskulitis. Curr Opin Rheumatol 14:29–35

    Article  PubMed  CAS  Google Scholar 

  3. Geltner D (1988) Therapeutic approaches in mixed cryoglobulinemia. Springer Seminar Immunopathol 10:103–113

    Article  CAS  Google Scholar 

  4. Lamprecht P, Gause A (2000) Kryoglobulinämische Vaskulitis. In: Gross WL (Hrsg) Therapie der Immunvaskulitiden. UNI-MED-Science-Verlag Bremen, S 120–123

    Google Scholar 

  5. Langland DR, Dowkins RL, Matz LR, Cobain TJ, Goatcher P, Papadimitriou JM (1980) Arthritis associated with a crystallizing cryoprecipitable IgG paraprotein. Am J Med 68:461–470

    Article  Google Scholar 

  6. Misiani R, Bellavista P (1996) Mixed cryoglobulinemia. A guide to drug treatment. Clin Immunother 5:115–121

    Google Scholar 

Literatur

  1. Hiltz RE, Cupps TR (1994) Cutaneous vasculitis. Curr Opin Rheumatol 6:20–24

    Article  PubMed  CAS  Google Scholar 

  2. Lotti T, Ghersetich I, Comacchi C, Jorizzo JL (1998) Cutaneous small-vessel vasculitis. J Am Acad Dermatol 39:667–687

    Article  PubMed  CAS  Google Scholar 

  3. Sais G, Vdaller A, Jucgala A, Gallardo F, Peyri J (1995) Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 131:1399–1402

    Article  PubMed  CAS  Google Scholar 

  4. Schulz H, Grabbe J, Trabandt A (2000) Purpura und kutane leukozytoklastische Angiitis. In: Gross WL (Hrsg) Therapie der Immunvaskulitiden. UNI-MED-Verlag, Bremen, S 130–132

    Google Scholar 

Literatur

  1. Aktualga E, Altac M, Özyazgan Y, Pazarli H, Tüzün Y, Yalçin B, Yasici H, Yurdakal S (1980) A double blind study of colchicine in Behçet’s disease. Haematologica 65:339–4

    Google Scholar 

  2. Alpsoy E, Yilmaz E, Basaran E (1984) Interferon therapy for Behçet’s disease. J Am Acad Dermatol 31:617–619

    Google Scholar 

  3. Bayraktar S, Izgi B, Tugal Tukun I, Urgancioglu M (1993) Low dose cyclosporine A plus methyl-prednisolone versus colchicine, cyclophosphamide plus methylprednisolone therapy in ocular involvement of Behçet’s disease. Medical Bulletin of Istanbul Medical Faculty 43:76–83

    Google Scholar 

  4. Chavis PS, Antonios SR, Tabbara KF (1992) Cyclosporine effects on optic nerve and retinal Behçet’s disease. Arch Ophthalmol 80:133–142

    CAS  Google Scholar 

  5. Faulds D, Goa KL, Benfield P (1993) Cyclosporine. A review of its pharmacodynamic and pharmacokinetic properties, an therapeutic use in immunoregulatory disorders. Drugs 45:953–1040

    Article  PubMed  CAS  Google Scholar 

  6. Hamuryuda V, Moral F, Yurdakul S, Mat C, Tuzun Y, Özyazgan Y, Direskeneli H, Akoglu T, Yasici H (1994) Systemic interferon Alpha 2b treatment in Behçet’s syndrome. J Rheumatol 21:1098–110

    Google Scholar 

  7. O’Duffy, JD, Robertson DM, Goldstein NP (1084) Chlorambucil in the treatment of uveitis and meningo-encephalitis of Behçet’s disease. Am J Med 76:75–84

    Article  Google Scholar 

  8. Oniki S, Kurakazu K, Kawata K (1976) Immuno-suppressive treatment of Behçet’s disease with cyclophosphamide. Jap J Ophthalmol 20:32–40

    Google Scholar 

  9. Suess R, Al-Ayoubi M, Ruzicka T (1993) Cyclosporine in Behçet’s disease. J Am Dermatol 29:101–102

    Google Scholar 

  10. Tabbara K (1983) Chlorambucil in Behçet’s disease. A reappraisal. Ophthalmology 90:906–908

    PubMed  CAS  Google Scholar 

  11. Towler HMA, Whiting PH, Forrester JV (1990) Combination low dose cyclosporine A and steroid therapy in chronic intraocular inflammation. Eye 4:514–520

    PubMed  Google Scholar 

  12. Whitcup SM, Salvo EC, Nussenblatt RB (1994) Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet’s disease. Am J Ophthalmol 118:39–45

    PubMed  CAS  Google Scholar 

  13. Yasici H, Pazarli H, Barnes CG, Tüzün Y, Özyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE, Yazici B, Somani S, Müftüoglu A (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322:281–28

    Article  Google Scholar 

  14. Yasici H, Barnes CG (1991) Practical treatment recommendations for pharmacotherapy of Behçet’s syndrome. Drugs 42:796–804

    Article  Google Scholar 

  15. Zouboulis CC, Treudler R, Orfanos CE (1993) Morbus Adamantiades-Behçet. Therapeutischer Einsatz von systemischem rekombinantem Interferon alpha 2a. Hautarzt 44:440–445

    PubMed  CAS  Google Scholar 

Literatur

  1. Gresser U (2001) Gicht (M10) In: Zeidler H, Zacher J, Hiepe F (Hrsg) Interdisziplinäre Rheumatologie. Springer, Berlin

    Google Scholar 

  2. Gröbner W, Walter-Sack I (1993) Gichttherapeutika — Physiologische Grundlagen, Klinik und Pharmakologie. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  3. Rosenthal AK (1998) Crystal arthropathies. In: Maddison PJ, Isenberg DA, Woo P, Glass DN (eds) Oxford Textbook of Rheumatology. Oxford Univ Press, Oxford New York Tokyo

    Google Scholar 

  4. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases 65:1312–1324

    Article  PubMed  CAS  Google Scholar 

  5. Zöllner N (Hrsg) unter Mitarbeit von Gresser U (1990) Hyperurikämie, Gicht und andere Störungen des Purinhaushaltes, 2. Aufl. Springer, Berlin Heidelberg New York London Paris Tokyo Hongkong Barcelona

    Google Scholar 

  6. Zöllner N (1994) Klinik und Therapie der Gicht. Dtsch Ärztebl 91:A-2234–2245

    Google Scholar 

Literatur

  1. Doherty M (1998) Calciumpyrophosphate dihydrate. In: Klippel JH, Dieppe PA (eds) Rheumatology. 2nd edn. Mosby, London Philadelphia St. Louis Sydney Tokyo

    Google Scholar 

  2. Fam AG (2000) What is new about crystals other than monosodium urate? Curr Opin Rheumatol 12:228–234

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Esterhai JL, Gelb I (1991) Adult septic arthritis. Orthop Clin North Amer 22: 503–514

    Google Scholar 

  2. Härle A, Tscheme H, Weissauer W (1988) Behandlungsstrategien bei Verdacht und beim Nachweis einer Gelenkinfektion nach intraartikulärer Injektion und Punktion. Z Unfallchir Berufskr 81:1–16

    Google Scholar 

  3. Härle A (1989) Infection management in total hip replacement. Arch Orthop Trauma Surg 108:63–71

    Article  PubMed  Google Scholar 

  4. Härle A (1991) Die Infektion bei Knieendoprothesen. Orthopäde 20:227–238

    PubMed  Google Scholar 

  5. Kusswetter W (ed) (1991) Infection in total hip replacement: clinical relevance and prophylaxis. Thieme, Stuttgart

    Google Scholar 

Literatur

  1. Eggers P, Cooper C, Hart DJ, Doyl DV, Coggon D, Spector TD (1995) Patterns of joint involvement in osteoarthritis of the hand: the Chingford Study. J Rheumatol 22:1509–1513

    Google Scholar 

  2. Elsner G, Nienhaus A, Beck W (1995) Arthrosen der Fingergelenke und der Daumensattelgelenke und arbeitsbedingte Faktoren. Gesundheitsw 57:786–791

    CAS  Google Scholar 

  3. Jäger M, Wirth CJ (1992) Praxis der Orthopädie. Thieme, Stuttgart New York

    Google Scholar 

  4. Rudigier J (1990) Kurzgefasste Handchirurgie. Hippokrates, Stuttgart

    Google Scholar 

  5. Treves R, Maheu E, Dreiser RL (1995) Therapeutic trials in digital osteoarthritis. A critical review. Rev Rhum Engl Edit 62:338–341

    Google Scholar 

  6. Zhang W et al (2007) EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66:377–388

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Hackenbroch MH (1989) Coxarthrose. In: Fehr K, Miehle W, Schattenkirchner M, Tillmann K (Hrsg) Degenerative Gelenkerkrankungen. Thieme, Stuttgart

    Google Scholar 

  2. Hochberg MC, Altman RD, Brand KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for medical management of osteoarthritis. Part I Osteoarthritis of the hip. Arthr Rheum 38:1535–1540

    Article  CAS  Google Scholar 

  3. Klippel JH, Dieppe PA (1994) Rheumatology. Mosby, St. Louis

    Google Scholar 

  4. Zhang W et al (2005) EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64:669–681

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Hackenbroch MH (1989) Gonarthrose. In: Fehr K, Miehle W, Schattenkirchner M, Tillmann K (Hrsg) Degenerative Gelenkerkrankungen. Thieme, Stuttgart

    Google Scholar 

  2. Hochberg MC, Altman RD, Brand KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for medical management of osteoarthritis. Part II Osteoarthritis of the knee. Arthr Rheum 38:1541–1546

    Article  CAS  Google Scholar 

  3. Jordan KM et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report fo a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145–1155

    Article  PubMed  CAS  Google Scholar 

  4. Klippel JH, Dieppe PA (1994) Rheumatology. Mosby, St. Louis

    Google Scholar 

Literatur

  1. Atlas SJ, Volinn E (1997) Classics from the spine literature revisited: a randomized trial of 2 versus 7 days of recommended bed rest for acute low back pain. Spine 22:2331–2337

    Article  PubMed  CAS  Google Scholar 

  2. BACK in time (1997) Kreuzschmerzen: Empfehlungen für Abklärung und Behandlung. FMH, Bern

    Google Scholar 

  3. Badura B (2000) Fehlzeiten-Report 1999. Springer, Berlin

    Google Scholar 

  4. Bendix T, Bendix AF, Busch E, Jordan A (1996) Functional restoration in chronic low back pain. Scand J Med Sci Sports 6:88–97

    Article  PubMed  CAS  Google Scholar 

  5. Brooker AS, Frank JW, Tarasuk VS (1997) Back pain claim rates and the business cycle. Soc Sci Med 45:429–439

    Article  PubMed  CAS  Google Scholar 

  6. Burnier D (1997) Après les nouveaux pauvres, voici les nouveaux invalides. Médecine et Hygiène 55:99–101

    Google Scholar 

  7. Burton AK, Waddell G (1998) Clinical guidelines in the management of low back pain. Baillieres Clin Rheumatol 12:17–35

    Article  PubMed  CAS  Google Scholar 

  8. Carette S, Marcoux S, Truchon R, Grondin C, Gagnon J, Allard Y, Latulipe MA (1991) Controlled trial of corticosteroid injections into facet joints for chronic low back pain. N Engl J Med 325:1002–1097

    Article  PubMed  CAS  Google Scholar 

  9. Carey TS, Garrett J, Jackman A, McLaughlin C, Fryer J, Smucker DR (1995) The outcomes and costs of care for acute low back pain among patients seen by primary care practitioners, chiropractors, and orthopedic surgeons. The North Carolina Back Pain Project. N Engl J Med 333:913–917

    Article  PubMed  CAS  Google Scholar 

  10. Cherkin DC, Deyo RA, Loeser JD, Bush T, Waddell G (1994) An international comparison of back surgery rates. Spine 19:1201–1206

    Article  PubMed  CAS  Google Scholar 

  11. Cherkin DC, Deyo RA, Wheeler K, Ciol MA (1994) Physician variation in diagnostic testing for low back pain. Who you see is what you get. Arthr Rheum 37:15–22

    Article  CAS  Google Scholar 

  12. Cherkin DC, Wheeler KJ, Barlow W, Deyo RA (1998) Medication use for low back pain in primary care. Spine 23:607–614

    Article  PubMed  CAS  Google Scholar 

  13. Cohen JE, Goel V, Frank JW, Bombardier C, Peloso P, Guillemin F (1994) Group education interventions for people with low back pain. An overview of the literature. Spine 19:1214–1222

    Article  PubMed  CAS  Google Scholar 

  14. Daltroy LH, Iversen MD, Larson MG, Lew R, Wright E, Ryan J, Zwerling C, Fossel AH, Liang MH (1997) A controlled trial of an educational program to prevent low back injuries (see comments). N Engl J Med 337:322–328

    Article  PubMed  CAS  Google Scholar 

  15. Di Fabio RP (1995) Efficacy of comprehensive rehabilitation programs and back school for patients with low back pain: a meta-analysis. Phys Ther 75:865–878

    PubMed  Google Scholar 

  16. Dreyfuss PH, Dreyer SJ, Herring SA (1995) Contemporary concepts in spine care. Lumbar zygapophysial (facet) joint injections. Spine 20:2040–2047

    Article  PubMed  CAS  Google Scholar 

  17. Frank JW, Brooker AS, DeMaio SE, Kerr MS, Maetzel A, Shannon HS, Sullivan TJ, Norman RW, Wells RP (1996) Disability resulting from occupational low back pain. Part II: What do we know about secondary prevention? A review of the scientific evidence on prevention after disability begins. Spine 21:2918–2929

    Article  PubMed  CAS  Google Scholar 

  18. Guzman J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C (2001) Multidisciplinary rehabilitation for chronic low back pain: systematic review. BMJ 322:1511–1516

    Article  PubMed  CAS  Google Scholar 

  19. Hadler NM (1995) The disabling backache. An international perspective. Spine 20:640–649

    PubMed  CAS  Google Scholar 

  20. Hansson TH, Hansson EK (2000) The effects of common medical interventions on pain, back function, and work resumption in patients with chronic low back pain. Spine 25:3055–3064

    Article  PubMed  CAS  Google Scholar 

  21. Hazard RG (1995) Spine update — functional restoration. Spine 20:2345–2348

    Article  PubMed  CAS  Google Scholar 

  22. Hofstee D (2002) Westindia sciatica trial: randomized controlled study of bed rest and physiotherapy for acute sciatica. J Neurosurg 96:45–49

    PubMed  Google Scholar 

  23. Honeyman PT, Jacobs EA (1996) Effects of culture on back pain in Australian aboriginals. Spine 21:841–843

    Article  PubMed  CAS  Google Scholar 

  24. Indahl A, Velund L, Reikeraas O (1995) Good prognosis for low back pain when left untampered. Spine 20:473–477

    PubMed  CAS  Google Scholar 

  25. Karjalainen K, Malmivaara A, van Tulder MW, Roine R, Jauhiainen M, Hurri H, Koes BW (2001) Multidisciplinary biopsychosocial rehabilitation for subacute low back pain in working-age adults. Spine 26:262–269

    Article  PubMed  CAS  Google Scholar 

  26. Keel P, Weber M, Roux E, Gauchat MH, Schwarz H, Jochum H (1998) Kreuzschmerzen: Hintergründe, Prävention, Behandlung — Basisdokumentation (BACK in time). FMH, Bern

    Google Scholar 

  27. Keel PJ, Perini Ch, Schütz-Petitjean D (1996) Chronifizierung von Rückenschmerzen — Hintergründe, Auswege. Eular, Basel

    Google Scholar 

  28. Koes BW, Assendelft WJ, van der Heijden GJ, Bouter LM, Knipschild PG (1991) Spinal manipulation and mobilisation for back and neck pain: a blinded review. BMJ 303:1298–1303

    PubMed  CAS  Google Scholar 

  29. Koes BW, Bouter LM, Beckerman H, van der Heijden GJ, Knipschild PG (1991) Physiotherapy exercises and back pain: a blinded review. BMJ 302:1572–1576

    PubMed  CAS  Google Scholar 

  30. Linton SJ, Bradley LA, Jensen I, Spangfort E, Sundell L (1989) The secondary prevention of low back pain: a controlled study with follow-up. Pain 36:197–207

    Article  PubMed  CAS  Google Scholar 

  31. Linton SJ, Hellsing AL, Anderson DJ (1993) A controlled study of the effects of an early intervention on acute musculoskeletal pain problems. Pain 54:353–359

    Article  PubMed  CAS  Google Scholar 

  32. Ljunggren AE, Weber H, Kogstad O, Thom E, Kirkesola G (1997) Effect of exercise on sick leave due to low back pain. A randomized, comparative, long-term study. Spine 22:1610–1616, discussion 1617

    Article  PubMed  CAS  Google Scholar 

  33. Malmivaara A, Hakkinen U, Aro T, Heinrichs ML, Koskenniemi L, Kuosma E, Lappi S, Paloheimo R, Servo C, Vaaranen V (1995) The treatment of acute low back pain — bed rest, exercises, or ordinary activity? N Engl J Med 332:351–355

    Article  PubMed  CAS  Google Scholar 

  34. Manniche C (1995) Assessment and exercise in low back pain. With special reference to the management of pain and disability following first time lumbar disc surgery. Dan Med Bull 42:301–313

    PubMed  CAS  Google Scholar 

  35. McDonald I, Daly J, Jelink V, Panetta F, Gutman J (1996) Opening Pandora’s box: the unpredictability of reassurance by a normal test result. BMJ 313:329–332

    PubMed  CAS  Google Scholar 

  36. McGuirk B, King W, Govind J, Lowry J, Bogduk N (2001) Safety, efficacy, and cost effectiveness of evidence-based guidelines for the management of acute low back pain in primary care. Spine 26:2615–2622

    Article  PubMed  CAS  Google Scholar 

  37. Meade TW, Dyer S, Browne W (1990) Low-back pain of mechanical origin: randomized comparison of chiropractic and hospital outpatient treatment. Eur J Chiropractic 38:92–107

    Google Scholar 

  38. Mitchell RI, Carmen GM (1990) Results of a multicenter trial using an intensive active exercise program for the treatment of acute soft tissue and back injuries. Spine 15:514–521

    Article  PubMed  CAS  Google Scholar 

  39. Nachemson AL (1994) Chronic pain — the end of the welfare state? Qual Life Res 3(suppl 1):S11–S17

    Article  PubMed  Google Scholar 

  40. Onghena P, Van Houdenhove B (1992) Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 49:205–219

    Article  PubMed  CAS  Google Scholar 

  41. Pfingsten M, Hildebrandt J, Leibing E, Franz C, Saur P (1997) Effectiveness of a multimodal treatment program for chronic low-back pain. Pain 73:77–85

    Article  PubMed  CAS  Google Scholar 

  42. Pincus T, Vlaeyen JW, Kendall NAS, Von Korff M, Kalauokalani DA, Reis S (2002) Cognitive-behavioral therapy and psychosocial factors in low back pain. Spine 27:E133–E138

    Article  PubMed  Google Scholar 

  43. Salerno S, Browning R, Jackson RP (2002) The effect of antidepressant treatment on chronic back pain. Arch Intern Med 162:19–24

    Article  PubMed  CAS  Google Scholar 

  44. Savage RA, Whitehouse GH, Roberts N (1997) The relationship between the magnetic resonance imaging appearance of the lumbar spine and low back pain, age, and occupation in males. Eur Spine J 6:106–114

    Article  PubMed  CAS  Google Scholar 

  45. Shekelle PG, Adams AH, Chassin MR, Hurwitz EL, Brook RH (1992) Spinal manipulation for low-back pain. Ann Intern Med 117:590–598

    PubMed  CAS  Google Scholar 

  46. Sinclair SJ, Hogg Johnson SH, Mondloch MV, Shields SA (1997) The effectiveness of an early active intervention program for workers with soft-tissue injuries. The Early Claimant Cohort Study. Spine 22:2919–2931

    Article  PubMed  CAS  Google Scholar 

  47. Stankovic R, Johnell O (1995) Conservative treatment of acute low back pain. A 5-year follow-up study of two methods of treatment. Spine 20:469–472

    Article  PubMed  CAS  Google Scholar 

  48. Task Force on Pain in the Workplace of the IASP (1995) Back pain in the workplace — management of disability in nonspecific conditions. IASP Press, Seattle

    Google Scholar 

  49. Triano JJ, McGregor M, Hondras MA, Brennan PC (1995) Manipulative therapy versus education programs in chronic low back pain. Spine 20:948–955

    Article  PubMed  CAS  Google Scholar 

  50. Turk DC, Okifuji A (1998) Psychological approaches in pain management: what works? Curr Opin Rheumatol 11:547–552

    CAS  Google Scholar 

  51. Van den Hoogen HJ, Koes BW, van Eijk JT, Bouter LM, Deville W (1998) On the course of low back pain in general practice: a one year follow up study (see comments). Ann Rheum Dis 57:13–19

    PubMed  Google Scholar 

  52. Van Tulder MW, Koes BW, Bouter LM (1997) Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized controlled trials of the most common interventions. Spine 22:2128–2156

    Article  PubMed  Google Scholar 

  53. Violinn E (1997) The epidemiology of low back pain in the rest of the world. Spine 22:1747–1754

    Article  Google Scholar 

  54. Von Korff M (1994) Studying the natural history of back pain. Spine 19: 2041S–2046S

    Article  Google Scholar 

  55. Waddell G (1987) A new clinical model for the treatment of low-back pain. Spine 12:632–644

    Article  PubMed  CAS  Google Scholar 

  56. Waddell G (1992) Biopsychosocial analysis of low back pain. Baillieres Clin Rheumatol 6:523–557

    Article  PubMed  CAS  Google Scholar 

  57. Waddell G (1996) Low back pain: a twentieth century health care enigma. Spine 21:2820–2825

    Article  PubMed  CAS  Google Scholar 

  58. Waddell G (1998) The Back Pain Revolution. Churchill Livingstone, Edinburgh

    Google Scholar 

  59. Waddell G, Feder G, McIntosh A, Lewis M, Hutchinson A (1996) Low back pain evidence review. Royal College of General Practitioners, London

    Google Scholar 

  60. Wahlgren DR, Atkinson JH, Epping Jordan JE, Williams RA, Pruitt SD, Klapow JC, Patterson TL, Grant I, Webster JS, Slater MA (1997) One-year follow-up of first onset low back pain. Pain 73:213–221

    Article  PubMed  CAS  Google Scholar 

  61. Weinstein SM, Herring SA, Derby R (1995) Contemporary concepts in spine care. Epidural steroid injections. Spine 20:1842–1846

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, Wernicke JF (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5–15

    Article  PubMed  CAS  Google Scholar 

  2. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA (1988) A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum 31:1535–1542

    Article  PubMed  CAS  Google Scholar 

  3. Bennett RM, Kamin M, Karim R, Rosenthal N (2003) Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114:537–545

    Article  PubMed  CAS  Google Scholar 

  4. Biasi G, Manca S, Manganelli S, Marcolongo R (1998) Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 18:13–19

    PubMed  CAS  Google Scholar 

  5. Brückle W, Lautenschlager J (1995) Die Therapie der generalisierten Tendomyopathie (Fibromyalgie-Syndrom). Akt Rheumatol 20:13–19

    Article  Google Scholar 

  6. Burckhardt CS (2006) Multidisciplinary approaches for management of fibromyalgia. Curr Pharm Des 12:59–66

    Article  PubMed  CAS  Google Scholar 

  7. Busch A, Schachter CL, Peloso PM, Bombardier C (2002) Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev CD003786

    Google Scholar 

  8. Cedraschi C, Desmeules J, Rapiti E, Baumgartner E, Cohen P, Finckh A, Allaz AF, Vischer TL (2004) Fibromyalgia: a randomised, controlled trial of a treatment programme based on self management. Ann Rheum Dis 63:290–296

    Article  PubMed  CAS  Google Scholar 

  9. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:1264–1273

    Article  PubMed  CAS  Google Scholar 

  10. Donmez A, Karagulle MZ, Tercan N, Dinler M, Issever H, Karagulle M, Turan M (2005) SPA therapy in fibromyalgia: a randomised controlled clinic study. Rheumatol Int 26:168–172

    Article  PubMed  Google Scholar 

  11. Farber L, Stratz T, Bruckle W, Spath M, Pongratz D, Lautenschlager J, Kotter I, Zoller B, Peter HH, Neeck G et al (2000) Efficacy and tolerability of tropisetron in primary fibromyalgia — a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol Suppl 113: 49–54

    Article  PubMed  CAS  Google Scholar 

  12. Goldenberg D (2006) Treatment of fibromyalgia in adults. Uptodate 14.3

    Google Scholar 

  13. Goldenberg DL, Felson DT, Dinerman H (1986) A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29:1371–1377

    Article  PubMed  CAS  Google Scholar 

  14. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C (1996) A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39:1852–1859

    Article  PubMed  CAS  Google Scholar 

  15. Goldenberg DL, Burckhardt C, Crofford L (2004) Management of fibromyalgia syndrome. JAMA 292:2388–2395

    Article  PubMed  CAS  Google Scholar 

  16. Jones KD, Burckhardt CS, Clark SR, Bennett RM, Potempa KM (2002) A randomized controlled trial of muscle strengthening versus flexibility training in fibromyalgia. J Rheumatol 29:1041–1048

    PubMed  Google Scholar 

  17. Keel PJ, Bodoky C, Gerhard U, Muller W (1998) Comparison of integrated group therapy and group relaxation training for fibromyalgia. Clin J Pain 14:232–238

    Article  PubMed  CAS  Google Scholar 

  18. Lautenschlager J (2000) Present state of medication therapy in fibromyalgia syndrome. Scand. J Rheumatol Suppl 113:32–36

    Article  PubMed  CAS  Google Scholar 

  19. Lemstra M, Olszynski WP (2005) The effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia: a randomized controlled trial. Clin J Pain 21:166–174

    Article  PubMed  Google Scholar 

  20. Mayhew E, Ernst E (2007) Acupuncture for fibromyalgia — a systematic review of randomized clinical trials. Rheumatology Oxford 46(5):801–804

    Article  PubMed  CAS  Google Scholar 

  21. Moldofsky H, Lue FA, Mously C, Roth-Schechter B, Reynolds WJ (1996) The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol 23:529–533

    PubMed  CAS  Google Scholar 

  22. Offenbacher M, Stucki G (2000) Physical therapy in the treatment of fibromyalgia. Scand J Rheumatol Suppl 113:78–85

    Article  PubMed  CAS  Google Scholar 

  23. Quijada-Carrera J, Valenzuela-Castano A, Povedano-Gomez J, Fernandez-Rodriguez A, Hernanz-Mediano W, Gutierrez-Rubio A, de la Iglesia-Salgado JL, Garcia-Lopez A (1996) Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 65: 221–225

    Article  PubMed  CAS  Google Scholar 

  24. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG (1991) Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 34:552–560

    Article  PubMed  CAS  Google Scholar 

  25. Samborski W, Stratz T, Sobieska M, Mennet P, Muller W, Schulte-Monting J (1992) Intraindividual comparison of whole body cold therapy and warm treatment with hot packs in generalized tendomyopathy. Z Rheumatol 51:25–30

    PubMed  CAS  Google Scholar 

  26. Samborski W, Stratz T, Lacki JK, Klama K, Mennet P, Muller W (1996) The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose. Mater Med Pol 28:17–19

    PubMed  CAS  Google Scholar 

  27. Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M (1995) Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, ketamine. Scand J Rheumatol 24:360–365

    Article  PubMed  CAS  Google Scholar 

  28. Thieme K, Gromnica-Ihle E, Flor H (2003) Operant behavioral treatment of fibromyalgia: a controlled study. Arthritis Rheum 49:314–320

    Article  PubMed  Google Scholar 

  29. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG (2004) A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19(suppl 1):S27–S35

    Article  PubMed  CAS  Google Scholar 

  30. Wolfe F, Cathey MA, Hawley DJ (1994) A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23:255–259

    Article  PubMed  CAS  Google Scholar 

  31. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB (1997) A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 40:1560–1570

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Compston J (2005) Prevention of vertebral fractures by strontium ranelate in post-menopausal women with osteoporosis. Osteoporos Int 16(suppl 1):S4–6:S4–S6

    Article  PubMed  Google Scholar 

  2. O’Neill S, MacLennan A, Bass S, Diamond T, Ebeling P, Findlay D, Flicker L, Markwell A, Nowson C, Pocock N, Sambrook P, Singh MF (2004) Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 33:910–919

    PubMed  Google Scholar 

  3. Pfeilschifter J (2005) Postmenopausal and steroid-induced osteoporosis guideline-orientated prevention and treatment. Internist (Berl) 46(suppl 1):S31–7:S31–S37

    Article  PubMed  Google Scholar 

  4. Ringe JD (1995) Osteoporose. Thieme, Stuttgart New York

    Google Scholar 

Literatur

  1. Bernau A, Heeg P (2003) Intraarticular punctures and injections: indications — prevention of infection — technique — complications. Orthopade 32:548–569

    PubMed  CAS  Google Scholar 

  2. Fischer M, Modder G (2002) Radionuclide therapy of inflammatory joint diseases. Nucl Med Commun 23:829–831

    Article  PubMed  Google Scholar 

  3. Kampen WU, Voth M, Pinkert J, Krause A (2007) Therapeutic status of radiosyno-viorthesis of the knee with yttrium [90Y] colloid in rheumatoid arthritis and related indications. Rheumatology (Oxford) 46:16–24

    Article  PubMed  CAS  Google Scholar 

  4. Kerschbaumer F, Kandziora F, Herresthal J, Hertel A, Hor G (1998) Combined arthroscopic and radiation synovectomy in rheumatoid arthritis. Orthopade 27: 188–196

    PubMed  CAS  Google Scholar 

  5. Kresnik E, Mikosch P, Gallowitsch HJ, Jesenko R, Just H, Kogler D, Gasser J, Heinisch M, Unterweger O, Kumnig G, Gomez I, Lind P (2002) Clinical outcome of radiosynoviorthesis: a meta-analysis including 2190 treated joints. Nucl Med Commun 23:683–688

    Article  PubMed  CAS  Google Scholar 

  6. Rau R, Schütte H (1983) Ergebnisse der Radiosynoviorthese mit Yttrium 90 bei chronischen Synovitiden — Eine prospektive Langzeituntersuchung. Teil 1: Gesamtergebnis und Einfluß lokaler Faktoren. Z Rheumatol 42:265–270

    PubMed  CAS  Google Scholar 

  7. Seidel W (2006) Radiosynoviorthesis. Z Rheumatol 65:239–244

    Article  PubMed  CAS  Google Scholar 

  8. van der Zant FM, Jahangier ZN, Moolenburgh JD, Swen WA, Boer RO, Jacobs JW (2006) Clinical effect of radiation synovectomy of the upper extremity joints: a randomised, double-blind, placebo-controlled study. Eur J Nucl Med Mol Imaging

    Google Scholar 

Literatur

  1. American Pain Society (2002) Clinical guideline for treatment of arthritis pain. www.ampainsoc.org

    Google Scholar 

  2. Sorge J, Menninger H, Thoden U, Hackental E (1992) Medikamentöse Schmerztherapie bei rheumatischen Erkrankungen. Der Schmerz 6:212–214

    Article  PubMed  CAS  Google Scholar 

  3. Zenz M, Jurna I (1993) Lehrbuch der Schmerztherapie: Grundlagen, Theorie und Praxis für Aus-und Weiterbildung. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

  4. Zenz M (1995) Taschenbuch der Schmerztherapie. Wissenschaftliche Verlagsgesellschaft, Stuttgart

    Google Scholar 

Literatur

  1. Moore RA, Trainer MR, Carroll D, Wiffen PJ, McQuay HJ (1998) Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 316:333–338

    PubMed  CAS  Google Scholar 

  2. Bolten W, Waldorf-Bolten E, Sarfert D, Lehmann M, Miehlke W (1990) Pharmakokinetische Untersuchungen nach zwei-bzw. vierwöchiger Felbinac-Gel-Applikation am Kniegelenk. Z Rheumatol 49:374–377

    PubMed  CAS  Google Scholar 

  3. Kidd BL, Mapp PI, Blake DR, Gibson SJ, Polak JM (1990) Neurogenic influences in arthritis. Ann Rheumat Dis 49:649–652

    PubMed  CAS  Google Scholar 

  4. Petersen U (1994) Statement für topische Antirheumatika. Dtsch Ärztebl 91:B-2608–2610

    Google Scholar 

  5. Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frölich C (1991) Diclofenac concentrations in synovial fluid and plasma after application in inflammatory and degenerative joint disease. Br J Clin Pharmac 31:537–541

    CAS  Google Scholar 

  6. Vaile JH, Davis P (1998) Topical NSAIDs for musculoskeletal conditions. Drugs 56(5):793–799

    Article  Google Scholar 

Literatur

  1. Buttgereit F, Song IH, Straub RH, Burmester GR (2005) Aktueller Stand zur Entwicklung neuer Glucocorticoid-Rezeptorliganden. Z Rheumatol 64(3):170–176

    Article  PubMed  CAS  Google Scholar 

  2. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arhtritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46(2): 3143–3150

    Article  PubMed  CAS  Google Scholar 

  3. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, Muzzonigro TA, Vogt M, Elder EM, Whiteside TL, Watkins SC, Herndon JH (2005) Gene transfer to humanjoints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 102(24):8698–8703

    Article  PubMed  CAS  Google Scholar 

  4. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month reults of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(8):2263–2271

    Article  PubMed  CAS  Google Scholar 

  5. Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61(10):883–888

    Article  PubMed  CAS  Google Scholar 

  6. Milner JM, Cawston TE (2005) Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy 4(3):363–375

    Article  PubMed  CAS  Google Scholar 

  7. Okazaki Y, Sawada T, Nagatani K, Komagata Y, Inoue T, Muto S, Itai A, Yamamoto K (2005) Effect of nuclear factor-kappa B inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis. J Rheumatol 32(8):1440–1447

    PubMed  CAS  Google Scholar 

  8. Park YW, Pryshchep S, Seyler TM, Goronzy JJ, Weyand CM (2005) B cells as a therapeutic target in autoimmune diseases. Expert Opin Ther Targets 9(3): 431–445

    Article  PubMed  CAS  Google Scholar 

  9. Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R (2001) ICE/Casepase-1 inhibitors as novel anti-inflammatroy drugs. Expert Opin Investig Drugs 10(7): 1207–1209

    Article  PubMed  CAS  Google Scholar 

  10. Ranganathan P (2005) Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 6(5):481–490

    Article  PubMed  CAS  Google Scholar 

  11. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52(3):818–825

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Antoni CE, Furst D, Manger B et al (2001) Outcome of pregnancy in women receiving Remicade (infliximab) for the treatment of Crohn’s disease or rheumatoid arthritis (abstract) Arthritis Rheum 44(suppl):S 153

    Google Scholar 

  2. Brooks PM, Needs CJ (1990) Antirheumatic drugs in pregnancy and lactation. Baillieres Clin Rheumatol 4:157–171

    Article  PubMed  CAS  Google Scholar 

  3. Chakravarty EF, Sanchez-Yamamoto D, Bush TM (2003) The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 30(2):241–246

    PubMed  Google Scholar 

  4. Davidson JM, Lindheimer MD (1982) Pregnancy in renal transplant recipients. J Reprod Me 27:613–621

    Google Scholar 

  5. Derksen RHWM, Bruinse HW, de Groot PG, Kater L (1994) Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 3:149–155

    Article  PubMed  CAS  Google Scholar 

  6. Hart CN, Naunton RF (1964) The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 80:407–412

    CAS  Google Scholar 

  7. Jarvis B, Faulds D (1999) Etanercept: a review of its use in rheumatoid arthritis. Drugs 57:945–966

    Article  PubMed  CAS  Google Scholar 

  8. Johns DG, Rutherford LD, Leighton PC, Vogel CL (1972) Secretion of methotrexate into human milk. Am J Obstet Gynecol 112:978–980

    PubMed  CAS  Google Scholar 

  9. Needs CJ, Brooks PM (1985) Antirheumatic medication in pregnancy. Br J Rheumatol 24:282–290

    Article  PubMed  CAS  Google Scholar 

  10. Ostensen M (2006) Antirheumatic therapy and reproduction. The influence on fertility, pregnancy and breast feeding. Z Rheumatol 65:217–224

    Article  PubMed  CAS  Google Scholar 

  11. Ostensen M (1994) Optimization of antirheumatic drug treatment in pregnancy. Clin Pharmacokinet 27:486–503

    Article  Google Scholar 

  12. Ostensen M (1998) Nonsteroidal anit-inflammatory drugs during pregnancy. Scand J Rheumatol Suppl 107:128–132

    PubMed  CAS  Google Scholar 

  13. Ostensen M, Brown ND, Chiang PK, Aarbakke J (1985) Hydroxychloroquine in human breast milk. Eur J Clin Pharmacol 28:357

    Article  PubMed  CAS  Google Scholar 

  14. Ostensen M, Skavdal K, Myklebust G, Tomassen Y, Aarbackke J (1986) Excretion of gold into human breast milk. Eur J Clin Pharmacol 31:251–252

    Article  PubMed  CAS  Google Scholar 

  15. Parke A (1992) The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses. Clin Rev Allergy 10:105–118

    PubMed  CAS  Google Scholar 

  16. Parke AL (1998) Intravenous gammaglobulin in pregnancy, the Connecticut experience. Scand J Rheumatol Suppl 107:103–104

    PubMed  CAS  Google Scholar 

  17. Parke A, West B (1996) Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 10:1715–1718

    Google Scholar 

  18. Roubenoff R, Hoyt J, Petri M et al (1988) Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Sem Arthr Rheum 18:88–110

    Article  CAS  Google Scholar 

  19. Slone D, Heinonen OP, Kaufmann DW et al (1976) Aspirin and congenital malformations. Lancet 1373–1375

    Google Scholar 

  20. Townsend RJ, Bendetti TJ, Erickson SH, Cengiz C, Gillespie WR, Gschwend J, Albert KS (1984) Exretion of ibuprofen in breast milk. Am J Obstet Gynecol 149:184–186

    PubMed  CAS  Google Scholar 

  21. Wolfe MS, Cordero JF (1985) Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J 290:1466–1467

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumaklinik 11, Leibnizstr. 23, 65191, Wiesbaden

    W. Bolten (Dr. und Chefarzt)

  2. Praxiszentrum, Bonifatius Str. 5, 81541, München

    K. Krüger (Prof. Dr.)

  3. 1. Medizinischen, Klinik des Zentralklinikums Augsburg, Frauentorstr. 22, 86152, Augsburg

    H. Kaiser (Prof. Dr. und ehem. Chefarzt)

  4. Rheumatologischen Klinik, Klinikum Rostock-Südstadt, Südring 81, 18059, Rostock

    M. Keysser (Prof. Dr. und ehem. Chefarzt)

  5. Rheumaklinik und Rheumaforschungsinstitut Aachen, Burtscheider Markt 24, 52066, Aachen

    E. Genth (Prof. Dr.)

  6. Medizinisch-Poliklinischen Institutes der Universität, Härtelstr. 16-18, 04107, Leipzig

    H. Häntzschel (Prof. Dr. und Direktor)

  7. Rheumatologischen Klinik, Städtisches Klinikum Kalkweg, Zu den Rehwiesen 9, 47055, Duisburg

    A. Ehlert (Dr. und Oberarzt)

  8. Abteilung für Orthopädische Rheumatologie Orthopädische Universitätsklinik, Waldkrankenhaus St. Marien, Rathsbergerstr. 57, 91054, Erlangen

    A. Wald (Dr.)

  9. Fachklinik, Reuthweg 4, 91074, Herzogenaurach

    B. Kladny (Prof. Dr. und Chefarzt)

  10. Internistischen Physiotherapie Klinik f. Innere Medizin II, Friedrich-Schiller-Universität, Erlanger Straße 101, 07740, Jena

    C. Uhlemann (Prof. Dr. und Leiterin)

  11. Rheumaklinik und Rheumaforschungsinstitut Aachen, Burtscheider Markt 24, 52066, Aachen

    E. Genth (Prof. Dr.)

  12. Rheumaklinik Berlin-Buch, Zepernicker Str. 1, 13125, Berlin

    E. Gromnica-Ihle (Prof. Dr. und ehem. Chefärztin)

  13. Internistisch-rheumatologische, Gemeinschaftspraxis, Jürgensallee 44, 22609, Hamburg

    E. Reinhold-Keller (PD Dr.)

  14. Innere Klinik IV, Friedrich-Schiller-Universität, Erlanger Allee 101, 07740, Jena

    G. Hein (Prof. Dr. und Leiter des Funktionsbereiches Rheumatologie und Osteologie) & O. Oelzner (PD Dr.)

  15. Klinik für Innere Medizin, Klinikum Rostock-Südstadt, Südring 81, 18059, Rostock

    G. Neeck (Prof. Dr., Chefarzt)

  16. Rheumakinderklinik, Gehfeldstraße 24, 82467, Garmisch-Partenkirchen

    H. Michels (Dr., Chefarzt)

  17. 1. Medizinischen Klinik, Krankenhaus Friedrichstadt, Friedrichstraße 41, 01067, Dresden

    H. Nüsslein (Prof. Dr. und Chefarzt)

  18. Rheumazentrum Ruhrgebiet, St. Josefs-Krankenhaus, Landgrafenstraß 15, 44652, Herne

    J. Braun (Prof. Dr., Chefarzt)

  19. Abteilung Rheumatologie, Allgemeines Krankenhaus Eilbek, Friedrichsberger Str. 60, 22081, Hamburg

    J. Wollenhaupt (Prof. Dr. und Chefarzt)

  20. Medizinischen Klinik IV, Klinikum Leverkusen, Dhünnberg 60, 51307, Leverkusen

    J. D. Ringe (Prof. Dr. und Leitender Arzt)

  21. Klinik für Endokrinologie Diabetologie und Rheumatologie, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf

    M. Schneider (Prof. Dr.)

  22. Abteilung Rheumatologie, Ev. Krankenhaus Oldenburg, Steinweg 13-17, 26122, Oldenburg

    M. Schwartz-Eywill (Dr., Chefarzt)

  23. Tal 6, 80331, München

    P. Herzer (Prof. Dr.)

  24. Zweigstelle Claragraben Postfach, Psychiatrische Universitätspoliklinik Basel, CH-4005, Basel, Schweiz

    P. Keel (Dr.)

  25. Rheumatologische Fachklinik, Evangelisches Fachkrankenhaus, Rosenstr. 2, 40882, Ratingen

    S. Wassenberg (Dr., Chefarzt)

  26. Klinik für Dermatologie und Allergologie, Krankenhaus Dresden-Friedrichstadt, Friedrichstraße 41, 01067, Dresden

    U. Wollina (Prof. Dr., Chefarzt)

  27. Kiefernhang 3, 39245, Vogelsang

    W. Keitel (Prof. Dr.)

  28. Orthopädischen Klinik, Universitätskrankenhaus Eppendorf, Martinistr. 52, 20246, Hamburg

    W. Rüther (Prof. Dr. und Direktor)

  29. Radiologischen und Nuklearmedizinischen Abteilung der Rheumaklinik, Burtscheider Markt 24, 52066, Aachen

    W. Vorbrüggen (Dr. und Leiter)

  30. Rheumaklinik und Rheumaforschungsinstitut Aachen, Burtscheider Markt 24, 52066, Aachen

    E. Genth (Prof. Dr.)

  31. Klinik für Anästhesiologie, Intensiv- und Schmerzmedizin, Bürkle-de-la-Camp-Platz 1, 44789, Bochum

    M. Zenz (Prof. Dr., Direktor) & M. Pantel

  32. Rheumaklinik 11, Leibnizstr. 23, 65191, Wiesbaden

    W. Bolten (Dr. und Chefarzt)

  33. Rheumatologischen Klinik, Klinikum Rostock-Südstadt, Südring 81, 18059, Rostock

    G. Keysser (Prof. Dr. ehem. Chefarzt)

  34. Rheumaklinik Berlin-Buch, Zepernicker Str. 1, 13125, Berlin

    E. Gromnica-Ihle (Prof. Dr. ehem. Chefärztin)

  35. Klinik für Endokrinologie Diabetologie und Rheumatologie, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf

    R. Fischer-Betz (Dr., Oberärztin)

Authors
  1. W. Bolten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Keysser
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Genth
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. Häntzschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Ehlert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Wald
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B. Kladny
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C. Specker
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C. Uhlemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E. Genth
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E. Gromnica-Ihle
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E. Reinhold-Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G. Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. G. Neeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. H. Michels
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. H. Nüsslein
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. H. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. J. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J. Wollenhaupt
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. J. D. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. M. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. M. Schwartz-Eywill
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. O. Oelzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. P. Herzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. P. Keel
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. R. Dreher
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. S. Wassenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. U. Wollina
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. W. Keitel
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. W. Rüther
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. W. Vorbrüggen
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. E. Genth
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. M. Zenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. M. Pantel
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. W. Bolten
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. G. Keysser
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. E. Gromnica-Ihle
    View author publications

    You can also search for this author in PubMed Google Scholar

  40. R. Fischer-Betz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2007 Steinkopff Verlag

    About this chapter

    Cite this chapter

    Bolten, W. et al. (2007). Medikamentöse Therapie. In: Qualitätssicherung in der Rheumatologie. Qualitätssicherung in der Rheumatologie, vol 1. Steinkopff. https://doi.org/10.1007/978-3-7985-1741-7_5

    Download citation

    • DOI: https://doi.org/10.1007/978-3-7985-1741-7_5

    • Publisher Name: Steinkopff

    • Print ISBN: 978-3-7985-1509-3

    • Online ISBN: 978-3-7985-1741-7

    • eBook Packages: Medicine (German Language)

    Publish with us

    Policies and ethics

    Search

    Navigation